Directory · KR
Biotechnology Research in South Korea
A register of firms and the professionals working at them in the Biotechnology Research sector based in South Korea. Browse the public index, then filter or export on Kipplo.
Companies
299 on file
3billion
3billion is dedicated to making rare disease diagnosis faster, more accurate, and accessible for patients everywhere. We provide AI-driven genetic testing covering all rare diseases, helping physicians deliver answers with confidence. Through our unique daily reanalysis system, patients continue to receive new diagnoses without additional cost. patients in 80+ countries have already been tested, in collaboration with 800+ medical institutions worldwide. In 2024, 3billion was listed on KOSDAQ, a recognition of our leading technology and global growth. Our mission is simple yet powerful: to ensure that every rare disease patient has a chance to receive an answer. For inquiries: support@3billion.io
51 to 200 staff
Easy Bio, Inc
Easy Bio, Inc. is an animal nutrition company based out of South Korea.
51 to 200 staff
Noul Co., Ltd
Noul Inc. has developed the next generation POC (Point-Of-Care) blood testing platform for resource-limited medical facilities, clinics, and local hospitals. Noul seeks to solve global challenges that threaten human life, to discover novel solutions, and to establish a new gold standard in POC blood testing. Noul’s solution aims to improve accessibility to proper health care by integrating innovations in biology, artificial intelligence, mobile technology, robotics, and software/hardware engineering. Noul has filed over 65 global patents, conducted more than seven field clinical trials, and has research partnerships with world-class global institutions.[Mission] We explore global challenges that threaten human health and life, discover novel potential solutions, and realize those possibilities.[Goal] 1. To contribute to eliminating malaria, tb, aids and other neglected diseases through innovative diagnostic platform. To proactively increase healthcare accessibility through next-generation blood diagnostics platform.
51 to 200 staff
Sartorius
Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. We help our customers simplify progress from drug discovery to manufacturing so that more people can have access to better medicine. With this, we are part of the solution in the fight against diseases worldwide. With innovative laboratory instruments and consumables, the Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. Based in Göttingen, Germany, Sartorius also has a strong global reach with more than 60 production and sales sites worldwide. We regularly expand our portfolio through the acquisition of complementary technologies. In 2024, Sartorius generated sales revenue of around 3.4 billion euros. Currently, more than 13,500 employees from around 110 nations are working for customers around the globe. Join our team, partner or collaborate with us.
10001+ staff
Abl Bio Inc
ABL Bio Inc.(Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com
51 to 200 staff
Dna Link
A frontier company in medical genetics research DNA Link is currently in collaboration with Korea’s most renowned clinical research specialists studying genetic effects of various diseases including diabetes, cardiovascular disease, cancer, atopy, and digestive diseases. Recent advancements in genomic research technology have enabled rapid analysis of whole genomes. Our current research projects utilize this technology to identify relationships between diseases and genomic content. In the past, genetic disease studies were conducted using a finite set of candidate genes as targets for research. While the results were valuable, the success of this approach was limited because diseases can depend on multiple factors, genetic and environmental. Modern genetic research methodologies take a more extended approach, considering the entire human genome to search for potential disease markers. In addition to identifying disease-related genes, DNA Link is working to develop disease diagnostic systems as well as personalized treatment methods. Using DNA Chip and Next Generation Sequencing technologies, we are currently developing cancer diagnostic systems by identifying common variants in DNA copy numbers for various cancers including lung cancer and breast cancer
51 to 200 staff
Edgc Eone-Diagnomics Genome Center
Global NGS Company, EDGC We provide the value for a healthy lifestyle by suggesting customized healthcare based on genome information. Through genome analysis, we have provided genetic screening tests to help people predict cancer and diseases and to offer personalized healthcare. We have developed cutting-edge technology for genome analysis through constant research and development and have established business networks to expand its influence on the global market. EDGC will become the company creating a healthy and happy life and a better future for all.
51 to 200 staff
Toolgen Inc
Toolgen is committed to conducting research for revamping genome editing technology and thus developing not only therapeutics for humans but plants and animals of which the genetic characters are modified by the editing.
51 to 200 staff
Bionsight
Bionsight is a drug discovery company that integrates the power of chemoproteomics and AI technologies to facilitate target identification and off-target profiling within the drug development process. We offer a chemoproteomics platform named Javelin, capable of identifying thousands of proteins, thereby enabling comprehensive protein-ligand interaction mapping on a proteome-wide scale. This state-of-the-art method provides numerous benefits for drug discovery. It empowers us to uncover multiple interactions, provides broad scope applicability to diverse targets, opens the potential to delve into the mechanisms of action and side effects, and presents a cutting-edge strategy to address previously "undruggable" targets.
11 to 50 staff
Genecast
The earlier you discover, the better you recover." Genecast is a biotechnology company specializing in cancer diagnosis using liquid biopsy. Our proprietary ADPS technology offers maximum detection sensitivity of quickly and accurately recognizing cancer mutation genes. With ADPS, we enhance treatment options, improve the success rate of targeted therapies, and enable early cancer detection. Our mission is to design a healthier 150-year life span by diagnosing previously undetectable diseases, treating the untreatable, and preventing illnesses more effectively. Our vision is to make cancer a manageable disease, contributing to a "healthier 150 years." Face cancer with ADPS. For more information, please visit our website.
11 to 50 staff
Qureator
Qureator is a pioneering AI-powered human biology platform company dedicated to revolutionizing drug discovery and development for complex diseases. Traditional drug discovery models—such as AI-driven computational predictions, animal testing, and 2D cell cultures—struggle to replicate human biology accurately, leading to high failure rates and costly inefficiencies. Qureator bridges this gap by integrating Next-Generation Microphysiological Systems (MPS) technology with cutting-edge AI-driven solutions, offering a human biology-based platform that mimics complex disease phenotypes and patient-specific responses. At the heart of Qureator’s platform are two groundbreaking technologies: Curiochips and Quricore. Curiochips integrates patient-derived cells into physiologically relevant, high-throughput models, allowing for more accurate disease replication and drug testing. Quricore, an AI-powered analytical engine, accelerates research by enabling rapid, high-precision hypothesis generation and data-driven decision-making. By leveraging advanced computational modeling and predictive analytics, Quricore enhances explainability and ensures robust insights, providing greater visibility into drug efficacy and toxicity for those driving advancements in drug discovery. This approach significantly reduces time and cost associated with traditional preclinical testing.
11 to 50 staff
Voronoi
VORONOI, a leading biotech in South Korea EGFR-Exon20Ins Lisenced out to ORIC Parmaceuticals in 2020 RET-Fusion Lisenced out to Inno.N in 2021 Anticipated upcoming IPO on KOSDAQ for 4Q, 2021
51 to 200 staff
Gc Cell
GC Cell stands at the forefront of cell therapy innovation with fully-integrated capability from research to commercialization. Offering customized solutions tailored to partners` needs, We provide end-to-end full value chain CDMO and bio logistics service. Our mission is to fast-track the innovation in cell and gene therapies, aiming to enhance the clinical outcomes of each and every patient, shaping the future of healthcare.
501 to 1000 staff
Proteina
PROTEINA has developed a first-in-class protein-protein interaction (PPI) analysis platform using proprietary 'single-molecule co-immunoprecipitation' technology. Our platform enables quantitative PPI measurements at the single-molecule level, delivering analyses with unparalleled accuracy and speed. PROTEINA has accumulated extensive know-how in developing assays measuring targeted PPIs as well as the analytic capability to model the efficacy of a drug based on its PPI metrics. Our mission is to revolutionize protein analysis; developing effective, new approaches to diagnosing diseases and discovering new drug candidates using our novel technology. For more information regarding PROTEINA, please visit us at
51 to 200 staff
Trial Informatics
We are Trial Informatics (TI), a Data Science company founded by a group of experienced medical doctors, health scientists, IT professionals, and data scientists in South Korea with the vision to reinvent clinical trial data with digital health technologies. Our mission is to digitalize clinical trial processes by capitalizing on Data Science, thereby supporting medical doctors, clinical researchers, contract research organizations (CROs), pharmaceutical companies, and other stakeholders to succeed in a clinical trial, small or large, with the state-of-art IT technologies and Data Science tools at every important stage of clinical development. Our solutions aim, among others, to streamline clinical research process, integrate data workflows of various stages, warehouse clinical trial data in a standardized manner, uncover new insights from past data, and serve as a digital platform for Decentralized Clinical Trials (DCTs). We have two child companies, TI Image and iAID. TI Image (https://tiimage.com), headquartered in Singapore and led by Dr. Amy Lee, is a global imaging CRO providing, most importantly, the central reading service for imaging clinical trials end-to-end on all the major therapeutic areas. iAID (https://iaidimage.com), headquartered in South Korea and led by Dr. Jeongjin Lee, is an AI company specializing in the AI medical imaging process, with invention of a high-speed web-PACS, which is now widely employed by the leading hospitals and medical research labs in South Korea. Contact: cs@trialinformatics.com
11 to 50 staff
Lg Chem Life Sciences Usa, Inc
At LG Chem Life Sciences USA, we aim to transform lives by inspiring science and leading innovation in the key therapeutic areas of Immunology, Oncology, and Metabolic diseases. Formerly LG Chem Life Sciences Innovation Center, LG Chem Life Sciences USA, located in Boston, MA, is the United States hub of LG Chem Life Sciences Company for global investment, development, and open innovation. Through our R&D pipeline and together with key strategic partners, we plan to bring disruptive technologies, new drugs, and digital healthcare forward.
51 to 200 staff
Pico Entech Co Ltd
PICO Entech (Enzyme Technology) is a unique bio-tech company founded in South Korea in 2014. We focus R&D for ALDH (Aldehyde Dehydrogenase) enzyme and related diseases arising from its deficiency. We've commercialized the ARC, ALDH Related Compounds, which we produce by performing special fermentation techniques with patent cocktailed microbes for the first time in the world. For its application products are the hangover treatment called 'KISLip', health supplements and more. You can find more information on our websites below,
11 to 50 staff
Sewon Cellontech Co., Ltd
Sewon Cellontech (listed on Korean Stock Market, KOSPI) is a leading korean bio-technology company producing regeneration medicine and medical devices, native collagen, and skin care product. We have developed and provided advanced cell therapy products for cartilage and bone regeneration, and we also supplied various collagen products. It has been marketing the skin care products, NovoSstrata and NovoFill, over the world. Since SEWON CELLONTECH has developed the patented collagen manufacturing, it has been dedicated to serving discerning customers fine formulation for skin with the specialized collagen. The collagen used for NOVOSTRATA and NovoFill is not a general collagen in the market but atelocollagen which is well-known as 100% genuine native collagen while others are structurally changed by extreme conditions. Based on the characteristics of the NovoStrata and NovoFill containing the atelocollagen, it gives much beneficial effects to skin regeneration and anti-aging actions. Moreover, the atelocollagen for cosmetics use is also available from us (Brand : RMS BioCollagen ) which could be better option for raw-materials of cosmetics. The atelocollagen has been listed on the INCI of USA PCPC(Personal Care Products Council).
501 to 1000 staff
Shaperon
Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc. In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of Nanobodies over conventional antibody-based medicines. We currently developing multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases.
11 to 50 staff
Theragen Bio
Global genome service provider and Platform-based biopharmaceutical company.
51 to 200 staff
Acebiome
AceBiome is one of South Korea’s fastest-growing microbiome innovators, specializing in science-driven probiotics for weight management and gut health, and expanding into natural solutions for joint health, bone support, and skin function. With deep expertise in microbiome science, AceBiome is best known for its proprietary strain Lactobacillus gasseri BNR17®, the first probiotic approved by Korea’s MFDS for body fat reduction. Its consumer brand BNRThin continues to lead the weight care category, particularly as a companion probiotic to GLP-1 therapies. Beyond digestive health, we’re expanding into healthy aging and life-cycle wellness with AnaParactin™, a plant-based joint and bone health line featuring clinically studied ParActin® (Andrographis paniculata) and Etnacare™, a beauty-from-within skin health support powered by Red Orange Complex H (ROCH). At AceBiome, we are committed to shaping the future of sustainable, holistic wellness with clinically proven solutions for both individuals and future generations.
51 to 200 staff
Amyloid Solution Inc
Erasing Alzheimer's Disease” is the mission of Amyloid Solution and the reason we exist. To erase the disorder, our R&D focuses on everything of Alzheimer’s disease. We search for fundamental culprits, interpret their systemic interactions, and discover methods for varied patient cases. Based on in-depth understanding of the disorder, we aim to discover and provide effective, safe, and diverse therapeutic solutions to overcome Alzheimer's disease. We are currently in international and domestic collaboration with key scientists and biopharma industries by open innovation and we are honored to receive proposals and invitations by future collaborations. We, Amyloid Solution, promise you that we will become a valuable and wise platform leading and supporting the challenge of Alzheimer drug discovery.
11 to 50 staff
Cj Bioscience
CJ Bioscience Global No.1 Microbiome Company CJ Bioscience is pioneering development of next-generation biopharmaceuticals for microbiome health with its leading edge in the field of ‘Wellness’. We aim to provide healthcare solutions for unmet medical needs by examining the relationships between human microbiomes and various diseases. In addition, CJ Bioscience, which uses leading world-class bioinformatic analysis technology, will discover promising candidates that can be used in the treatment of incurable diseases, and accelerate the development of new drugs utilizing our ‘Ez-Mx™ Platform’ to become the global No. 1 microbiome company. Microbiome We plan to enter clinical trials (Phase 1) of a new drug development pipeline for treatment of immuno-oncology, autoimmune, and CNS (Central Nervous System) diseases and to promote technology export through joint research with Big Pharma. Also, we are constructing a ‘Ez-Mx™ Platform’ by expanding on cohort studies (comparative disease research) and securing global microbiome big data. The next generation of genomic analysis We plan to expand our business area from next generation sequencing (NGS)-based microbiome genomic analysis to microbial infection diagnosis. We will further upgrade our state-of-the-art NGS and bioinformatics (BI) total solution services. We are expanding the global business capabilities of EzBioCloud, a global standard bioinformatic analysis service made for researchers combining a curated microbiome database and artificial intelligence (AI) technology, and TrueBacID, the world's first genome-based infection diagnosis service. In addition, through the global launch of Gut Inside, an intestinal.
51 to 200 staff
Cubebio
CUBEBIO is a cancer specialized company contributing to human health promotion through early diagnosis of cancer. Through our unique technology and product development, we have been firmly establishing our competitive advantages to become the world’s leading company in the global cancer market. CUBEBIO’s mission is to transform the cancer diagnostic market paradigm. We are aiming to lead the global popularization of cancer self-diagnostic devices that are both accurate, fast, and easy-to-use for customers. We will strive to promote people’s health and happiness and thus become the company that our customers adore. For more information, please visit our website.
11 to 50 staff
